



Study of PTCH1 Gene as a Prognostic Marker to Predict Imatinib Response on Egyptian CML Patients in Chronic Phase

Thesis

*Submitted for Partial Fulfilment of
Master Degree in Clinical Haematology*

By

Omnia Shoukry Abdel Fattah
M.B.B.Ch.

Supervised by

Dr / Mohamed Mahmoud Moussa

*Professor of Internal Medicine-Clinical Haematology
Faculty of Medicine, Ain Shams University*

Dr/ Mohamed Tarif Hamza

*Assistant Professor of Clinical Pathology
Faculty of Medicine, Ain Shams University*

Dr / Mary Gamal Naguib

*Lecturer of Internal Medicine- Clinical Haematology
Faculty of Medicine, Ain Shams University*

Faculty of Medicine - Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبَحَانَكَ لَا مَعْلَمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Dr / Mohamed Mahmoud Moussa**, Professor of Internal Medicine-Clinical Haematology, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Dr/ Mohamed Tarif Hamza**, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for his sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Dr / Mary Gamal Maguib**, Lecturer of Internal Medicine- Clinical Haematology, Faculty of Medicine, Ain Shams University, for her great help, outstanding support, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Omnia Shoukry Abdel Fattah

List of Contents

Title	Page No.
List of Tables.....	5
List of Figures	8
List of Abbreviations.....	11
Introduction	- 1 -
Aim of the Study	17
Review of Literature	18
Chronic Myeloid Leukaemia (CML)	18
Definition	18
History of CML	19
Epidemiology.....	21
Clinical presentation and Staging	24
Pathogenesis	29
Philadelphia negative chronic myloid leukemia	33
PTCH1 Gene	36
CML WORKUP	38
Treatment	41
I. Supportive therapy	41
II. Treatment of CP-CML	41
III. Treatment of advanced CML.....	102
CML with pregnancy.....	104
CML in pediatrics.....	112
Patients and Methods.....	114
Results.....	126
Discussion	156
Summary.....	159
Conclusion	161
Recommendations	162
References	163
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Classification schemes in CML, AP and BP	29
Table (2):	Major clinical trials of imatinib in CP CML	49
Table (3):	Risk calculation table: age in years, spleen in centimeters below costal margin, blast cells, eosinophils in peripheral blood, all should be measured before treatment	64
Table (4):	Recommended Frequencies of Response Assessment in Patients with CML	65
Table (5):	Evaluation of Overall Responses to First-Line TKI Treatment by the European LeukemiaNet (ELN) and the National Comprehensive Cancer Network (NCCN).....	66
Table (6):	Early treatment response milestones.....	67
Table (7):	Monitoring response to TKI therapy and mutational analysis.....	68
Table (8):	Requirements of TKI discontinuation in clinical practice.....	71
Table (9):	Definitions of BCR-ABL1 mutation.....	77
Table (10):	Acquired alteration associated with TKI resistance in CML patients.....	80
Table (11):	Indication for allo-SCT.....	86
Table (12):	Role and Timing of allo-HSCT.....	89
Table (13):	Patients were classified according to their imatinib response	117
Table (14):	Buffer RLT was added to pelleted leucocytes.....	118
Table (15):	Genomic DNA elimination reaction components.	120
Table (16):	Reverse transcription master mix preparation.	121

List of Tables cont...

Table No.	Title	Page No.
Table (17):	Distribution of CML Patients in Chronic Phase according to their all parameters regarding Sex, Age (years), FISH, PTCH1 express.....	126
Table (18):	Distribution of all parameters regarding Sex, Age (years), PTCH1 express. Level, Hb, TLC, PLT in control group (n=10).	129
Table (19):	Comparison between patients and control group according to demographic data.....	131
Table (20):	Comparison between patients and control group according to PTCH1 expression level.	133
Table (21):	Comparison between patients and control group according to laboratory data.....	134
Table (22):	Comparison between response and no response according to demographic data in patients group.	136
Table (23):	Comparison between response and no response according to FISH in patients group.	136
Table (24):	Comparison between response and no response according to PTCH1 expression level in patients group.....	137
Table (25):	Comparison between response and no response according to PCRin patients group.	139
Table (26):	Comparison between response and no response according to laboratory data in patients group.....	141

List of Tables cont...

Table No.	Title	Page No.
Table (27):	Correlation between PTCH1 expression level with Age (years), FISH, Hb before, TLC before, PLT before, Hb after, TLC after and PLT after, using Pearson Correlation Coefficient in patients group.....	144
Table (28):	Correlation between after 6m PCR-ABL-PCR with Age (years), FISH, Hb before, TLC before, PLT before, Hb after, TLC after and PLT after, using Pearson Correlation Coefficient in patients group.....	147
Table (29):	Comparison between PTCH1 ≤ 2 and PTCH1 > 2 according to Age (years), FISH, Hb before, TLC before, PLT before, Hb after, TLC after and PLT after in patients group.....	150
Table (30):	Comparison between PCR after 6m (≤ 1.6) and PCR after 6m (> 1.6) according to Age (years), FISH, Hb before, TLC before, PLT before, Hb after, TLC after and PLT after in patients group.	151

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Clinical and haematological criteria for the definition of AP and BP according to WHO and ELN Accelerated phase Blast phase A.....	28
Figure (2):	Structure of the p210BCR ABL fusion protein and mechanisms of leukemogenesis.....	32
Figure (3):	Philadelphia chromosome	33
Figure (4):	The Philadelphia chromosome, which is a diagnostic karyotypic abnormality for chronic myelogenous leukemia, is shown in this picture of the banded chromosomes 9 and 22	39
Figure (5):	Single TKI.....	45
Figure (6):	Multi TKI.....	46
Figure (7):	Flow chart summarizing when mutation analysis is recommended in CML patients treated with imatinib first-line	75
Figure (8):	Sequence analysis for the ABL mutation (BCR-ABL transcript)	76
Figure (9):	Incidence of major molecular response (MMR) and molecular response of a 4.5-log reduction (MR4.5).....	105
Figure (10):	NCCN guidelines version 4.2018, Chrnoic myeloid leukemia.	110
Figure (11):	CML	111
Figure (12):	Pie chart sex distribution of the patients group.	127

List of Figures *cont...*

Fig. No.	Title	Page No.
Figure (13):	Pie chart improvement distribution of the patients group.	128
Figure (14):	Pie chart sex distribution of the sex group.	130
Figure (15):	Bar chart between patients and control group according to sex.....	132
Figure (16):	Bar chart between patients and control group according to age (years).	132
Figure (17):	Bar chart between patients and control group according to PTCH1.....	133
Figure (18):	Bar chart between patients and control group according to laboratory data.....	135
Figure (19):	Bar chart between improvement and no improvement according to PTCH1 expression level in patients group.	138
Figure (20):	Bar chart between improvement and no improvement according to PCR in patients group.....	140
Figure (21):	Bar chart between improvement and no improvement according to Hb.....	142
Figure (22):	Bar chart between improvement and no improvement according to TLC.	142
Figure (23):	Bar chart between improvement and no improvement according to PLT.....	143
Figure (24):	Scatter plot between PTCH1 expression level with Hb.	145
Figure (25):	Scatter plot between PTCH1 expression level with TLC.	145

List of Figures *cont...*

Fig. No.	Title	Page No.
Figure (26):	Scatter plot between PTCH1 expression level with PLT.	146
Figure (27):	Scatter plot between PTCH1 expression level with Hb.	146
Figure (28):	Scatter plot between after 6m PCR-ABL PCR with TLC.	148
Figure (29):	Receiver-operating characteristic (ROC) curve for prediction not-improvement of CML Patients in Chronic Phase using the PTCH1 and PCR after 6m.	149
Figure (30):	Histogram of imatinib response and PTCH 1 expression.....	152
Figure (31):	Imatinib response and gender	153
Figure (32):	Imatinib response and level of PTCH 1 expression	154
Figure (33):	Progression free survival	155

List of Abbreviations

Abb.	Full term
ABMT	Autologous bone marrow transplantation
ACAs	Additional chromosomal abnormalities
ALL.....	Acute lymphoblastic leukemia
alloSCT.....	Allogeneic stem cell transplantation
AML.....	Acute myeloid leukemia
AP	Accelerated phase
BCC	Basal cell carcinoma
BP	Blast phase
BUS	Busulfan
CCyR.....	Complete cytogenetic response
CHR.....	Complete hematologic response
CIBMTR	Center for international blood and marrow transplant research
CML.....	Chronic myeloid leukemia
CNL	Chronic Neutrophilic Leukemia
CP.....	Chronic phase
CTL.....	Cytotoxic T lymphocytes
DLI.....	Donor lymphocyte infusion
EBMT	European Society for Blood and Marrow Transplantation
ELN	European leukemia.Net
ET.....	Essential thrombocytosis
FISH.....	Fluorescence in situ hybridization
GVHD	Graft versus host disease
GVL	Graft versus leukemia
Hh pathway.....	Hedgehog signaling pathway
HU	Hydroxyurea
MMR.....	Major molecular response

List of Abbreviations cont...

Abb.	Full term
<i>NCCN</i>	<i>National comprehensive cancer network</i>
<i>OS</i>	<i>Overall survival</i>
<i>PAH</i>	<i>Pulmonary arterial hypertension</i>
<i>PCR</i>	<i>Polymerase chain reaction</i>
<i>Ph</i>	<i>Philadelphia chromosome</i>
<i>TFR</i>	<i>Treatment-free remission</i>
<i>TKI</i>	<i>Tyrosine kinase inhibitors</i>
<i>TRM</i>	<i>Transplantation-related mortality</i>
<i>TSG</i>	<i>Tumor suppressor gene</i>
<i>WHO</i>	<i>World health organization</i>

INTRODUCTION

Chronic myelogenous leukemia (CML), also known as Chronic myeloid leukemia, is a myeloproliferative disorder characterized by increased proliferation of the granulocytic cell line without the loss of their capacity to differentiate. It accounts for 20% of all leukemia's affecting adults (**Radich, 2018**).

The clinical manifestations of CML are insidious, changing somewhat as the disease progresses through its 3 phases (chronic, accelerated, and blast). Signs and symptoms in the chronic phase are Fatigue, weight loss, Low-grade fever and splenomegaly on routine assessment(**Radich, 2018**).

Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a specific genetic lesion, the Philadelphia chromosome, harboring the BCR-ABL oncogene. Since then, it has become a paradigm for the discovery of molecular mechanisms and targeted therapeutic approaches in the field of hematologic neoplasias (**Sawyers, 1999**).

The median age of onset of CML is 50 years; the peak incidence occurs between ages 50 and 60. There is no sex preference. The first phase of the disease, the chronic phase, terminates in a second, more acute or abrupt course, called the blast phase. Sometimes there is an intervening short-lived phase between the chronic and blast phases called the

accelerated phase, characterized by a more gradual increase in blast cells in the peripheral blood, progressive anemia, thrombocytopenia, and increasing splenomegaly. The median survival approximates 3 to 5 years (**Sawyers, 1999**).

CML is often suspected on the basis of a complete blood count, which shows increased granulocytes of all types, typically including mature myeloid cells. Basophils and eosinophils are almost universally increased; this feature may help differentiate CML from a leukemoid reaction (**Tefferi, 2006**).

CML is characterized by a balanced genetic translocation, t (9;22)(q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome (ph) (**Jabbour and Kantarjian, 2018**).

The BCR-ABL1 fusion gene results in the formation of a unique gene product, the BCR-ABL1 fusion protein. This protein product includes an enzymatic domain from the normal ABL1 with tyrosine kinase catalytic activity. It is this deregulated tyrosine kinase that is implicated in the pathogenesis of CML (**Druker, 2001**).

The medications used for patients with CML aim at delaying the onset of the accelerated or blastic phase. This has

traditionally included a myelosuppressive agent to achieve hematologic remission, but more effective drugs—successively, interferon alfa then and targeted therapy with tyrosine kinase inhibitors such as imatinib mesylate, have gained greater importance. Chemotherapy may be used, particularly in preparation for bone marrow or hematopoietic stem cell transplantation. Cytogenetic monitoring was required at 3, 6, 12, and 18 months. Molecular monitoring was required every 3 months. On the basis of the degree and the timing of hematologic, cytogenetic, and molecular results, the response to first-line imatinib was defined as optimal, suboptimal, or failure (*Baccarani, 2009*).

The PTCH1 gene provides instructions for producing the patched-1 protein, which functions as a receptor. Receptor proteins have specific sites into which certain other proteins, called ligands, fit like keys into locks. A protein called Sonic Hedgehog is the ligand for the patched-1 receptor. Together, ligands and their receptors trigger signals that affect cell development and function. PTCH1 is called a tumor suppressor gene. It's Cytogenetic Location: 9q22.32, which is the long (q) arm of chromosome 9 at position 22.32 (*Adolphe, 2006*).

PTCH1 expression at diagnosis should be considered a promising molecular marker for predicting the probability of imatinib response in patients with CP-CML. These findings may facilitate clinicians' ability to tailor a first-line TKI treatment to the individual patient. PTCH1 expression does not